Product Information
CYCLOSPORINE MODIFIED 100 MG is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.2335 per EA under NDC 00093902065. Its NADAC has been published 271 times since Jul 28, 2021.
FDA first approved this application on Mar 29, 2005. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093902065
Classification
Generic
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
Generic (ANDA)
FDA Application
ANDA065110FDA Approved
3/29/2005
TE Code
AB1
On Market Since
6/8/2021
Pharmacological Classes
Price Statistics
The NADAC for CYCLOSPORINE MODIFIED 100 MG has been published 271 times since Jul 28, 2021, and over the history we have for it it has declined 42.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2335 per EA |
|---|---|
| All-time high | $2.4440 (Aug 14, 2024) |
| All-time low | $1.2257 (Mar 18, 2026) |
| 52-week high | $1.7564 |
| 52-week low | $1.2257 |
| Median price | $1.5089 |
| Average price | $1.5719 |
| Largest weekly change | +45.7% (Jul 17, 2024) |
| Weeks tracked | 271 |
| Tracking since | Jul 28, 2021 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOSPORINE MODIFIED 100 MG?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOSPORINE MODIFIED 100 MG, manufactured by Teva Pharmaceuticals USA Inc., is $1.2335 per EA (NDC 00093902065), effective Sep 30, 2026.
How has the price of CYCLOSPORINE MODIFIED 100 MG changed over time?
Over the history we have for it, the NADAC for CYCLOSPORINE MODIFIED 100 MG has declined 42.1%. It has been tracked across 271 weekly CMS publications since Jul 28, 2021.
What are the highest and lowest recorded NADAC prices for CYCLOSPORINE MODIFIED 100 MG?
Since Jul 28, 2021, the NADAC for CYCLOSPORINE MODIFIED 100 MG has ranged from a low of $1.2257 (Mar 18, 2026) to a high of $2.4440 (Aug 14, 2024), with a median of $1.5089 per EA.
Are there cheaper alternatives to CYCLOSPORINE MODIFIED 100 MG?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CYCLOSPORINE MODIFIED 100 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures CYCLOSPORINE MODIFIED 100 MG?
CYCLOSPORINE MODIFIED 100 MG (NDC 00093902065) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.